DS3790a + Combination drug + Combination drug
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Jan 16, 2026 → Nov 30, 2030
NCT ID
NCT07220616About DS3790a + Combination drug + Combination drug
DS3790a + Combination drug + Combination drug is a phase 1/2 stage product being developed by Daiichi Sankyo for Hematological Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07220616. Target conditions include Hematological Malignancies.
What happened to similar drugs?
0 of 1 similar drugs in Hematological Malignancies were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07220616 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Hematological Malignancies